Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05035212 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults.
A Phase 3 study of Lower Respiratory Tract Illness, sponsored by Pfizer.
- Active
- Registry status
- Phase 3
- Development phase
- 38,861
- Enrollment target
- 20
- Study locations
NCT05035212: Active Phase 3 study of Lower Respiratory Tract Illness, sponsored by Pfizer.
NCT05035212 is a Phase 3 study of Lower Respiratory Tract Illness that is active but no longer recruiting, run by Pfizer. The registered enrollment target is 38,861 participants, above the 769-participant average among 15,282 other Phase 3 trials with a reported enrollment target (4953% higher). The trial reports 20 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05035212, a Phase 3 study of Lower Respiratory Tract Illness, is active but no longer recruiting, sponsored by Pfizer.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 38,861 participants
- Enrollment target
- 20
- Study locations
Study Summary
Efficacy Study: This randomized, double-blinded, placebo-controlled Phase 3 study is designed to assess the safety, immunogenicity, and efficacy of a single dose of RSVpreF in the prevention of LRTI-RSV in adults: * At a dose of 120µg. * In adults 60 years of age and older. * The duration of the study for each participant will be up to approximately 24 months. * The study will be conducted in the United States, Canada, Netherlands, Finland, Argentina, Japan and South Africa. Substudy A: This study is an extension of the efficacy study and was designed to evaluate the safety and immunogenicity of a second dose of RSVpreF when administered after a dosing interval of approximately 2 years: * At a dose of 120µg (as studied in the Phase 3 Efficacy Study) * Blood samples will be collected for antibody testing. * The duration of the study for each participant will be up to approximately 18 months. * The study will be conducted in the United States and Argentina. Substudy B: This study was designed to evaluate the safety and immunogenicity of a second dose of RSVpreF when administered after a dosing interval of approximately 1 year: * At a dose of 120µg (as studied in the Phase 3 Efficacy Study) * Blood samples will be collected for antibody testing. * The duration of the study for each participant will be up to approximately 18 months. * The study will be conducted in Argentina. Substudy C: This study was designed to evaluate the safety and immunogenicity of a second dose of RSVpreF when administered after a dosing interval of either 3 or 4 years: * At a dose of 120µg (as studied in the Phase 3 Efficacy Study) * Participants will receive either placebo or a second dose of RSVpreF approximately 3 or 4 years after receiving the initial dose of RSVpreF in the main efficacy study. * Blood samples will be collected for antibody testing. * The duration of the study for each participant will be up to approximately 24 months. * The study will be conducted in the United Stat
Primary Outcome
Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)-confirmed RSV A and/or RSV B- associated acute respiratory illness (ARI) is assessed. LRTI-RSV is defined as an ARI with 2 or more of the lower respiratory signs/symptoms lasting more than 1 day during the same illness, plus RT-PCR-confirmed RSV infection within 7 days of ARI symptom onset. Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)-confirmed RSV A and/or RSV B- associated acute respiratory illness (ARI) is assessed. LRTI-RS
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL RSVpreF
Study Locations (20)
Arizona
- Lenzmeier Family Medicine / Avacare - Glendale
- Phoenix Clinical LLC - Phoenix
- HOPE Research Institute - Phoenix
- The Pain Center of Arizona - Phoenix
- HOPE Research Institute - Phoenix
- Cognitive Clinical Trials, LLC - Phoenix
- Headlands Research - Scottsdale - Scottsdale
- Alliance for Multispecialty Research, LLC - Tempe
- HOPE Research Institute - Tempe
- Noble Clinical Research - Tucson
- The Institute for Liver Health dba Arizona Clinical Trials - Tucson
California
- Hope Clinical Research - Canoga Park
- eStudySite - Chula Vista
- Benchmark Research - Colton
- West Coast Research - Dublin
- Marvel Clinical Research 002, LLC - Huntington Beach
- Chemidox Clinical Trials - Lancaster
Alabama
- St. Vincent's Birmingham (Pharmacy) - Birmingham
- St. Vincent's Birmingham - Birmingham
- Medical Affiliated Research Center - Huntsville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38,861 participants |
| Start Date | 2021-08-31 |
| Est. Completion | 2027-01-18 |
| Phase | Phase 3 |
What the registry record for NCT05035212 still lists
NCT05035212 is an interventional study that assigns participants to a tested intervention. Its 38,861 participants enrollment target places it among the larger protocols in the corpus, above the 769-participant average among 15,282 other Phase 3 trials with a reported enrollment target (4953% higher).
The record links to 1 condition, with Lower Respiratory Tract Illness appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05035212 names 20 study sites across 3 states, led by Arizona, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT05035212 about?
NCT05035212 is a clinical study titled "Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults.". Efficacy Study: This randomized, double-blinded, placebo-controlled Phase 3 study is designed to assess the safety, immunogenicity, and efficacy of a single dose of RSVpreF in the prevention of LRTI-RSV in adults: * At a dose of 120µg. * In adults 60 years of age and older. * The duration of the st...
What is the current status of trial NCT05035212?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 38,861 participants. The study started on 2021-08-31. Estimated completion is 2027-01-18.
What conditions does trial NCT05035212 study?
This clinical trial studies the following conditions: Lower Respiratory Tract Illness.
What interventions are being tested in trial NCT05035212?
The interventions under investigation include: Placebo (BIOLOGICAL), RSVpreF (BIOLOGICAL).
Who is sponsoring clinical trial NCT05035212?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05035212 being conducted?
This trial has 20 study locations across Alabama, Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05035212's enrollment target sits among peer trials
38,861 3rd of 2000 higher than 1,998 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01255748 · 40,000 participants
Registry Study for Radiation Therapy Outcomes
- NCT04994756 · 40,000 participants
Stroke Thrombectomy and Aneurysm Registry
- NCT06768814 · 40,000 participants · NA
Overdose Recovery and Care Access (ORCA) Qualitative Stakeholder Interviews and County-level Data
- NCT07109427 · 40,000 participants · NA
Impact of an Electronic Health Record Maintenance Alert on PSA Screening Rates in a 10-Hospital Integrated Health System
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI